Radioligand Therapy Eligibility in EU Could Surge Tenfold by 2035

A new study in The Lancet Regional Health—Europe projects that patients eligible for radioligand therapies (RLTs) in the EU-27 could skyrocket from 10,700–13,200 in 2025 to 125,900–182,600 by 2035. Radioligand therapies are targeted treatments that use radioactive molecules to treat certain cancers by targeting specific cellular markers. Researchers analyzed treatment scenarios in Germany, France, Italy, and Spain to understand healthcare infrastructure demands. The findings underscore the urgent need for long-term planning regarding workforce training, hospital capacity, and resource allocation to meet anticipated demand across Europe.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: June 10, 2026 at 10:11 AM



